<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Abvc Biopharma, Inc. — News on 6ix</title>
<link>https://6ix.com/company/abvc-biopharma-inc</link>
<description>Latest news and press releases for Abvc Biopharma, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 24 Feb 2026 13:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/abvc-biopharma-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835418d78dffbe2df0e0e7d.webp</url>
<title>Abvc Biopharma, Inc.</title>
<link>https://6ix.com/company/abvc-biopharma-inc</link>
</image>
<item>
<title>ABVC BioPharma Provides Corporate and Structural Update</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-provides-corporate-and-structural-update</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-provides-corporate-and-structural-update</guid>
<pubDate>Tue, 24 Feb 2026 13:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - February 24, 2026 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company focused on botanical-derived therapeutics and commercial ingredient platforms, today pr...</description>
</item>
<item>
<title>ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-highlights-safety-profile-133000414</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-highlights-safety-profile-133000414</guid>
<pubDate>Tue, 02 Dec 2025 13:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - December 2, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) today addressed recent public discussions surrounding attention-deficit/hyperactivity disorder (ADHD) treatment in the United States[...</description>
</item>
<item>
<title>ABVC BioPharma Highlights Strengthened Operations at BioKey's 28,176-sq.-ft. Silicon Valley Facility, Featuring U.S.-Based Multi-Product Capabilities Including Functional Foods, and Expansion Outlook Supporting Up to [1,000] Jobs by 2030</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-highlights-strengthened-operations-133000181</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-highlights-strengthened-operations-133000181</guid>
<pubDate>Wed, 26 Nov 2025 13:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - November 26, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) today announced that its wholly owned subsidiary, BioKey (Cayman), Inc. ("BioKey"), has strengthened its operational platform and lo...</description>
</item>
<item>
<title>ABVC Receives US$250,000 From ForSeeCon; Vitargus(R) Total Licensing Fee up to US$33.5 Million; US$816,000 Already Received</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-receives-us-250-000-133000326</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-receives-us-250-000-133000326</guid>
<pubDate>Fri, 21 Nov 2025 13:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - November 21, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC) announced today that ForSeeCon Eye Corporation ("ForSeeCon") has made an additional US$250,000 payment under the existing ophthalmic...</description>
</item>
<item>
<title>ABVC BioPharma Receives US$240,000 Licensing Payment From OncoX BioPharma; Total Licensing Payments Reach Approximately US$2.53 Million</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-us-240-133000508</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-us-240-133000508</guid>
<pubDate>Tue, 18 Nov 2025 13:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - November 18, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company") today announced that it has received an additional US$240,000 licensing payment from its partner OncoX BioPharma, Inc. ("OncoX") un...</description>
</item>
<item>
<title>ABVC BioPharma Reports 230% YoY Licensing Revenue Growth and 181% Asset Expansion in Q3 2025</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-reports-230-yoy-130000303</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-reports-230-yoy-130000303</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>SILICON VALLEY, CA - November 3, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc.. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in central nervous system (CNS), ophthalmology, and oncology/hematology indicatio...</description>
</item>
<item>
<title>ABVC BioPharma Receives Additional US$100,000 Licensing Payment from OncoX BioPharma, Bringing Total Payments to US$695,950</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-additional-us-110000289</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-additional-us-110000289</guid>
<pubDate>Fri, 31 Oct 2025 11:00:00 GMT</pubDate>
<description>OncoX's "Technology Performance Asset" Business Model Drives ABVC's Licensing Portfolio Revaluation SILICON VALLEY, CA - October 31, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) today announced that its oncology partner OncoX BioPharma...</description>
</item>
<item>
<title>ABVC BioPharma Highlighted by U.S. Financial Media as One of the Best Biotech Investments; Q3 Licensing Revenue Reaches $1.27 Million, With Clear Clinical Progress Across CNS and Oncology</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-highlighted-u-financial-113000472</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-highlighted-u-financial-113000472</guid>
<pubDate>Fri, 17 Oct 2025 11:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - October 17, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (C...</description>
</item>
<item>
<title>ABVC BioPharma Has Received a Cumulative Total of US$566,000 Under ForSeeCon Licensing Agreement Supporting GMP Facility in Hsinchu for Vitargus(R) Production</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-received-cumulative-total-113000291</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-received-cumulative-total-113000291</guid>
<pubDate>Wed, 08 Oct 2025 11:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - October 8, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company") today announced that it has received a US$70,000 licensing payment from its partner, ForSeeCon Eye Corporation ("ForSeeCon"), under th...</description>
</item>
<item>
<title>ABVC BioPharma Reports US$1.03 Million in Total Licensing Revenues Collected in Q3 to Date, Highlighting High-Margin Business Model</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-reports-us-1-113000094</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-reports-us-1-113000094</guid>
<pubDate>Fri, 19 Sep 2025 11:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - September 19, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc.. (NASDAQ: ABVC) ("ABVC" or the "Company") today announced that it has received a licensing payment of US$145,950 from OncoX BioPharma, Inc. ("OncoX") under the terms of the...</description>
</item>
<item>
<title>ABVC BioPharma Receives $450,000 in Licensing Payments From OncoX BioPharma in Q3 2025</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-450-000-113000145</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-450-000-113000145</guid>
<pubDate>Fri, 29 Aug 2025 11:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - August 29, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("ABVC" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies in oncology, ophthalmology, and central nervous system (CN...</description>
</item>
<item>
<title>BioLite, Inc., an ABVC BioPharma Subsidiary, Receives $230,000 Milestone Payment from AiBtl, Advancing Botanical Drug Licensing Collaboration</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/biolite-inc-abvc-biopharma-subsidiary-062500225</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/biolite-inc-abvc-biopharma-subsidiary-062500225</guid>
<pubDate>Wed, 27 Aug 2025 06:25:00 GMT</pubDate>
<description>Silicon Valley, CA - (NewMediaWire) - August 27, 2025 - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hemato...</description>
</item>
<item>
<title>ABVC BioPharma Receives $100,000 Milestone Payment From ForSeeCon, Strengthening Vitargus(R) Licensing Deal</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-100-000-113000467</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-100-000-113000467</guid>
<pubDate>Fri, 22 Aug 2025 11:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - August 22, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematolog...</description>
</item>
<item>
<title>ABVC BioPharma, Inc. Reports 103% Year-Over-Year Asset Growth and Secures $350K in Post-Quarter Licensing Revenue in Q2 2025</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-inc-reports-103-113000715</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-inc-reports-103-113000715</guid>
<pubDate>Thu, 14 Aug 2025 11:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - August 14, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, central nervous system (CNS) disorders, and oncology...</description>
</item>
<item>
<title>BioKey Stands as a Strategic U.S. Pharmaceutical Platform Amid Global Tariff Shifts</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/biokey-stands-strategic-u-pharmaceutical-110000355</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/biokey-stands-strategic-u-pharmaceutical-110000355</guid>
<pubDate>Fri, 08 Aug 2025 11:00:00 GMT</pubDate>
<description>ABVC's 28,000 sq ft Silicon Valley Manufacturing Facility Stands Ready as Global Supply Chains Realign and Trust-based Localization Becomes Key SILICON VALLEY, CA - August 8, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a cl...</description>
</item>
<item>
<title>ABVC BioPharma Gains Confidence From International Investors to Support Growth Path</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-gains-confidence-international-113000935</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-gains-confidence-international-113000935</guid>
<pubDate>Wed, 06 Aug 2025 11:30:00 GMT</pubDate>
<description>SILICON VALLEY, CA - August 6, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology...</description>
</item>
<item>
<title>OncoX Deepens ABVC Alliance</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/oncox-deepens-abvc-alliance-110000194</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/oncox-deepens-abvc-alliance-110000194</guid>
<pubDate>Fri, 01 Aug 2025 11:00:00 GMT</pubDate>
<description>CEO Yen Wen Pin's IPO Vision Gains Traction as OncoX Expands Pipeline SILICON VALLEY, CA - August 1, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in...</description>
</item>
<item>
<title>ABVC BioPharma Strengthens Oncology Partnership With $100,000 Milestone Payment From OncoX BioPharma</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-strengthens-oncology-partnership-130000204</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-strengthens-oncology-partnership-130000204</guid>
<pubDate>Thu, 24 Jul 2025 13:00:00 GMT</pubDate>
<description>Total licensing revenue crosses $1.046 million; strategic collaboration with OncoX evolves toward expanded product development and global oncology footprint SILICON VALLEY, CA - July 24, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a cl...</description>
</item>
<item>
<title>ABVC BioPharma Records $100,000 Licensing Milestone From ForSeeCon, Strengthening Eye Health Program</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-records-100-000-130000592</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-records-100-000-130000592</guid>
<pubDate>Fri, 18 Jul 2025 13:00:00 GMT</pubDate>
<description>With Total Milestone Payments Reaching $946,000, ABVC Deepens Its Ophthalmology Focus Through a High-potential Partnership With ForSeeCon SILICON VALLEY, CA - July 18, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopha...</description>
</item>
<item>
<title>ABVC BioPharma Receives $150K Milestone From AiBtl, Bringing Total Licensing Revenue to $846K Across Strategic Partnerships</title>
<link>https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-150k-milestone-213214651</link>
<guid isPermaLink="true">https://6ix.com/company/abvc-biopharma-inc/news/abvc-biopharma-receives-150k-milestone-213214651</guid>
<pubDate>Thu, 10 Jul 2025 21:32:14 GMT</pubDate>
<description>Licensing-first Strategy Continues to Deliver Non-dilutive Revenue; ABVC Positions Itself as a Leader in CNS-focused Botanical Therapeutics SILICON VALLEY, CA - July 10, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinica...</description>
</item>
</channel>
</rss>